Bioscience News: Breaking Bioscience News, Comments and Articles. - Page: 5

Cardio3 and Cellular Dynamics join IPO hopefuls

Two stem cell specialists will soon become the latest to take their chances on the public markets: Cardio3 Biosciences and Cellular Dynamics have both announced plans for initial public offerings (IPOs). Cellular Dynamics (based in Madison,.....

New Florida Law Takes a Major Step in Promoting Access to Biologic Medicines

Contains Four of BIO’s Five Principles on Biologic Product Substitution The Biotechnology Industry Organization (BIO) commends Florida Governor Rick Scott for signing House Bill 365, designed to create a pathway for the substitution of interchangeable biologic medicines. While not including all 5 of

North Shore InnoVentures Adds Six New Companies to its Technology Incubator

Startup Companies in Biotech and Cleantech Fields Join Massachusetts Incubator and Business Accelerator North Shore InnoVentures, (NSIV) one of New England’s leading technology incubators and business accelerators, announced today that six new startup companies in the cleantech and life sciences sectors have joined as members since March 2013,...

MichBio Hosts First Michigan Biosciences Capitol Day

MichBio members will display the strength and diversity of the state’s bio-industry today at the first Michigan Biosciences Capitol Day to be held at the Capitol Building in Lansing, Michigan. Legislators are able to stop by and find out how the bio-industry contributes to Michigan’s economy, creating jobs today and for the future. The...

Structure-Based Drug Design Conference in Boston, Starting June 19 PLUS These 62 Start-ups and Small Companies Will Transform Drug Delivery Technology

FARMINGTON, Conn., June 5, 2013 /PRNewswire-iReach/ -- From Global Information and MCD Group, a new report "Early Stage Drug Delivery Technologies" profiles 62 start-ups and small companies that have interest in forming new partnerships or receiving funding to enable further development and eventual commercialization of their drug delivery technologies. All of the companies investigated are d...

Safeguard Scientifics to Host Investor Day on October 8, 2013

Save the Date! Safeguard Scientifics, Inc. (NYSE:SFE) will be hosting its 7th Annual Investor Day at the New York Stock Exchange on Tuesday, October 8, 2013 from 8:00 a.m. – 11:30 a.m. EDT. Investor Day 2013 will offer the investor community an opportunity to hear from executives from Safeguard’s

New Website Dedicated to Sufferers of Melanoma

FRIENDSWOOD, Texas, June 5, 2013 /PRNewswire/ -- Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of SkinMelanoma.com, a website created to educate melanoma patients, their families and healthcare providers about this rare, but aggressive form of skin cancer. SkinMelanoma tells the story of this disease, its treatment and the importance...

NewYorkBIO Elects Six New Board Directors, Focusing on Chief Executives

NewYorkBIO, the voice of New York’s bioscience industry, announced today that the Association’s membership has elected six new Directors to the Board. In keeping with the organization’s mission to serve the expanding bioscience community across New York State, NewYorkBIO’s new Board reflects the diverse industry sectors and research areas that comprise...

Precision BioSciences Files Patent Infringement Lawsuit against Lonza Related to GS XceedTM Gene Expression System

Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has filed a patent infringement lawsuit against Lonza Group (LONN.VX) and a number of its affiliates in the U.S. District Court for the District of Delaware. The lawsuit seeks a ruling that Lonza’s importation into the United States and the use, offer for sa...

RBCC Poised To Gain Share Of $142 Billion Market

With innovative drug therapies gaining in popularity, Rainbow BioSciences, LLC, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC), continues its partnering talks with a transdermal patch company as it readies to take a share of the booming $142 billion U.S. drug delivery market. Industry insiders forecast the transdermal delivery market...

QB3 to Collaborate with Johnson & Johnson Innovation on New Incubator

SAN FRANCISCO, June 5, 2013 /PRNewswire-USNewswire/ -- The California Institute for Quantitative Biosciences (QB3) has signed an agreement with Johnson & Johnson Innovation to allocate 5,000 square feet of the space in QB3's new 24,000-square foot biosciences incubator in San Francisco to launch Janssen Labs @QB3. Under the collaboration, Johnson & Johnson will have an exclusive agreement...

QB3 to Collaborate with Johnson & Johnson Innovation on New Incubator

SAN FRANCISCO , June 5, 2013 /PRNewswire-USNewswire/ -- The California Institute for Quantitative Biosciences (QB3) has signed an agreement with Johnson & Johnson Innovation to allocate 5,000 square feet of the space in QB3's new 24,000-square f...

[ViewRay]'s Series D round brings in $17.4mm

MRI-guided cancer radiotherapy company [ViewRay Inc.] brought in $17.4mm through the sale of Series D-2 preferred shares to seven unnamed investors. Including the current round and a $10mm debt sale in 2011, the company has raised $100mm from backers...

Cardio3 planning European IPO

Cardio3 BioSciences S.A. (Mont-Saint-Guibert, Belgium) said it plans to raise an undisclosed amount in an IPO on NYSE Euronext Brussels and NYSE Euronext Paris. Kempen is global coordinator, and Kempen and Invest Securities are joint bookrunners. Car...

Pressure BioSciences says new high throughput design for platform technology expected to accelerate growth

Pressure BioSciences (OTCQB:PBIO) says it has a new high throughput (HT) design for its patented pressure cycling technology (PCT) that will integrate its platform with the automated HT sample preparation and analytical system formats installed in th...

UPDATE 1-Belgian heart drug firm Cardio3 plans to IPO in Paris, Brussels

BRUSSELS, June 4 (Reuters) - Belgian heart drug specialist Cardio3 BioSciences is planning a stock market debut in Brussels and Paris, it said on Tuesday, without providing details on the timing or size of the initial public offering (IPO).

Alcresta Announces Board Appointments, Strengthening Team as Company Prepares for Nutritional Product Commercialization

Nutritional Industry Veteran Steve Dubin Appointed to Board of Directors; Gaetan Crucke and Chris Bleck Join Product Advisory Board Alcresta™, a science-driven company developing innovative enzyme-based nutritional products for adults, infants, and patients battling acute conditions or chronic diseases, today announced the appointment of Steve Dubin,...

Belgian heart drug firm Cardio3 plans to IPO in Paris, Brussels

BRUSSELS, June 4 (Reuters) - Belgian heart drug specialist Cardio3 BioSciences is planning a stock market debut in Brussels and Paris, it said on Tuesday, without providing details on the timing or size of the initial public offering (IPO).

NYBA is Now NewYorkBIO, Reflecting Expanded Scope and Mission of New York’s Life Science Trade Association

In the 23 years since its inception, the New York Biotechnology Association (NYBA) has grown from a network of 6 local companies and universities to become the largest bioscience trade group in New York, representing over 250 member organizations in every sector of the life science industry, from therapeutics and diagnostics to medical devices and biotech...

Pressure BioSciences Announces Core Technology Breakthrough

SOUTH EASTON, Mass., June 4, 2013 /PRNewswire/ -- During their presentation at the Marcum SmallCap Conference on May 30, 2013 (http://wsw.com/webcast/marcum/pbio/), Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") announced they have achieved and passed proof-of-principle objectives in their multi-year investment into the development of a high throughput ("HT") system for their pa...

Introducing JeNu Active-Youth™ Skincare System

SEATTLE, June 4, 2013 /PRNewswire/ -- Seattle-based JeNu Biosciences is launching the new JeNu Active-Youth Skincare System, the first and only professional-quality, at-home system to combine the power of ultrasound technology with two clinically proven anti-aging technologies to help users achieve more youthful-looking eyes and luscious, fuller-looking lips in as little as 1 week. (Photo:...

Article Highlights the Value of PreDx® Testing of Prediabetic Patients in the Primary Care Setting

EMERYVILLE, Calif., June 4, 2013 /PRNewswire/ -- An article published in Clinical Diabetes describes the clinical value of PreDx testing for more effective management of prediabetes patients in the primary care practice setting.  The PreDx test is a predictive multi-biomarker fasting blood test developed by Tethys Bioscience, Inc., that stratifies adult patients with prediabetes int...

Mid-Atlantic Crossroads announces launch of Double HELIX

Mid-Atlantic Crossroadsannounces the launch of Double HELIX (Health, Education, Life Sciences, and Internet eXchange), the new high-performance point of presence located at the Institute for Bioscience and Biotechnology Research in Rockville, Marylan...

Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology

CHICAGO, June 4, 2013 /PRNewswire/ -- Ambit Biosciences Corporation (Nasdaq: AMBI) announced today that multiple presentations from the Phase 2 ACE study of quizartinib (AC220), a FLT3 inhibitor, were presented at the Annual Meeting of the American Society of Clinical Oncology. Data presented included analyses of the 333 patients with relapsed or refractory acute myeloid leukemia (AML) from...

Protagonist Therapeutics Raises $14 Million in Series B Venture Financing

MENLO PARK, Calif., June 4, 2013 /PRNewswire/ -- Protagonist Therapeutics, Inc. today announced the completion of a $14 million Series B venture financing. The financing, led by new investor Johnson & Johnson Development Corporation (JJDC), also included the participation of Series A investors Lilly Ventures and Starfish Ventures (Melbourne, Australia).  The new funding will sup...